Novo Nordisk says new data show Victoza advantage
COPENHAGEN Nov 27 (Reuters) - Denmark's Novo Nordisk on Tuesday said new data showed an advantage for type two diabetes patients given its diabetes drug Victoza compared with rival drugs from Merck & Co and Amylin Pharmaceuticals Inc.
The world's biggest insulin producer said in a statement that more type two diabetes patients given Victoza achieved an average blood sugar level below seven percent than those given Merck's sitagliptin (Januvia) or Amylin's exenatid BID.
For non-diabetics, the usual blood sugar level is between 4 and five percent, while a level of 6.5 percent is considered good blood sugar control for people with diabetes.
Improving blood sugar control can help reduce the risk of complications associated with diabetes.
The study had monitored patients given Victoza (liraglutide) over 26 weeks, compared with patients given the two rival treatments, Novo Nordisk said.
- Thousands of Gaza civilians flee after Israeli warning |
- Three dead, two wounded in Pasadena, California shootings
- Teen survivor of Texas shootings says slain family members 'in much better place'
- Rape and murder of 13-year-old spark debate in junta-ruled Thailand
- One man killed as shell from Ukraine hits Russian border town: reports